Crystal form of uconafil and preparation method thereof

By preparing four new crystal forms of ukennafil (crystalline B,crystalline C,crystalline D,crystalline E) and its corresponding methods, the problem of poor stability of ukennafil free alkali is solved, and the problem of poor stability of ukennafil is achieved. The stability and good solubility under high temperature, high humidity and light conditions are improved, and the reliability and product yield of industrial production are improved.

CN119019403APending Publication Date: 2024-11-26YANGTZE RIVER PHARM GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310604010.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Uknafil free alkali is prone to crystallization, producing unnecessary impurities, affecting its storage and transfer, resulting in poor stability and affecting industrial production.

Method used

Provide four new crystal forms of ukennafil (crystalline B,crystalline C,crystalline D,crystalline E) and preparation methods, including room temperature suspension method, anti-solvent addition method and evaporation crystallization method, through specific The solvent combination and treatment conditions were used to obtain a stable new crystal form.

Benefits of technology

The new crystal form maintains stability under high temperature, high humidity and light conditions, improves storage and industrial production conditions, and improves reactant utilization and product yield.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019403A_ABST
    Figure CN119019403A_ABST
Patent Text Reader

Abstract

According to the novel crystal form of the uconafil and the preparation method of the novel crystal form of the uconafil, the crystal form B, the crystal form C, the crystal form D and the crystal form E are not subjected to crystal form transformation after being placed under the conditions of high temperature and high humidity, the stability is superior to that of the crystal form A, and storage and industrial production of the uconafil are facilitated. In addition, the crystal form B, the crystal form C, the crystal form D and the crystal form E further have good hygroscopicity and show good solubility in various solvents. Therefore, the crystal form provided by the invention is beneficial to improving the utilization rate of reactants, so that the yield of subsequent products is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of drug crystal forms, and in particular to a crystal form of Ukalafil and a method for preparing the same. Background Art

[0002] Polymorphism refers to the ability of a compound to assume at least two crystalline arrangements in the solid state. In the pharmaceutical industry, the polymorphic form of a compound is of great interest because polymorphism can affect the solubility and stability of the compound. The study of polymorphism also helps reduce the risk and cost of problems during large-scale production.

[0003] Yonkenafil hydrochloride is the hydrochloride of Yonkenafil, which can be used to treat sexual dysfunction and other diseases related to the function of phospholipase 5, and has good clinical advantages. Its chemical name is 2-[2-ethoxy-5-(4-ethylpiperazine-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one monohydrochloride, and has the following structure:

[0004]

[0005] Studies have found that Ukenafil, as a key intermediate in the preparation of Ukenafil hydrochloride, is prone to crystal transformation during storage, producing unnecessary impurities, thereby affecting its storage and transfer. In view of this, it is urgent to provide a new Ukenafil crystal form and a preparation method thereof to overcome the defects of the prior art. Summary of the invention

[0006] The purpose of this application is to provide a new crystal form of Ukenafil and a preparation method thereof, so as to overcome the defect of instability of Ukenafil free base, and facilitate better storage and industrial production of Ukenafil. The specific technical scheme is as follows:

[0007] In a first aspect, the present application provides a crystalline form of Ukenafil represented by formula (I);

[0008]

[0009] Wherein, the crystal form is selected from any one of crystal form B, crystal form C, crystal form D, and crystal form E;

[0010] The X-ray powder diffraction pattern of the crystalline form B includes the following characteristic peaks shown at 2θ angles: 4.953°±0.2°, 9.860°±0.2°, 11.132°±0.2°, 15.708°±0.2°, 17.081°±0.2°, 21.843°±0.2°, 24.120°±0.2°, 24.395°±0.2°, 24.863°±0.2°, 27.306°±0.2°;

[0011] The X-ray powder diffraction pattern of the crystalline form C includes the following characteristic peaks shown at 2θ angles: 9.246°±0.2°, 10.796°±0.2°, 12.167°±0.2°, 13.859°±0.2°, 16.025°±0.2°, 17.455°±0.2°, 17.666°±0.2°, 18.053°±0.2°, 18.710°±0.2°, 20.883°±0.2°;

[0012] The X-ray powder diffraction pattern of the crystalline form D includes the following characteristic peaks shown at 2θ angles: 9.205°±0.2°, 10.638°±0.2°, 11.587°±0.2°, 13.852°±0.2°, 14.874°±0.2°, 15.657°±0.2°, 17.601°±0.2°, 18.558°±0.2°, 19.306°±0.2°, 21.468°±0.2°;

[0013] The X-ray powder diffraction pattern of the crystalline form E includes the following characteristic peaks shown at 2θ angles: 9.383°±0.2°, 9.963°±0.2°, 11.820°±0.2°, 15.848°±0.2°, 16.329°±0.2°, 17.181°±0.2°, 17.803°±0.2°, 20.185°±0.2°, 22.985°±0.2°, and 24.499°±0.2°.

[0014] The second aspect of the present application provides a method for preparing a crystalline form of Ukenafil, wherein the preparation method is selected from any of the following methods: a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method;

[0015] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20° C. to 30° C. for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from at least one of water, methyl tert-butyl ether, C1-C4 alcohol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), n-hexane, or n-heptane;

[0016] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from at least one of acetone, tetrahydrofuran, DMSO, methanol, or DMF; the third solvent is selected from at least one of methyl tert-butyl ether, n-hexane, n-heptane, isopropyl ether, or water;

[0017] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from at least one of methyl tert-butyl ether, C1-C4 alcohol, dichloromethane, chloroform, methyl acetate or tetrahydrofuran.

[0018] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form B, and the preparation method of the crystal form B is selected from a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method; preferably, the anti-solvent addition method;

[0019] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil; the first solvent is selected from at least one of water and methyl tert-butyl ether;

[0020] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20°C to 30°C, filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from acetone, tetrahydrofuran or DMSO; the third solvent is selected from methyl tert-butyl ether, n-hexane or n-heptane; preferably, the second solvent is acetone, and the third solvent is methyl tert-butyl ether; or, preferably, the second solvent is tetrahydrofuran, and the third solvent is methyl tert-butyl ether, n-hexane or n-heptane; or, preferably, the second solvent is DMSO, and the third solvent is n-heptane;

[0021] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methyl tert-butyl ether.

[0022] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form C, and the preparation method of the crystal form C is selected from a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method; preferably, the room temperature suspension method;

[0023] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil; the first solvent is selected from methanol, ethanol, n-propanol, n-butanol, isopropanol, sec-butanol, tert-butanol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, DMSO or DMF; preferably tetrahydrofuran;

[0024] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20°C to 30°C, filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from methanol, tetrahydrofuran or DMF; the third solvent is selected from n-hexane or isopropyl ether; preferably, the second solvent is methanol or tetrahydrofuran, and the third solvent is isopropyl ether; or, preferably, the second solvent is DMF, and the third solvent is n-hexane;

[0025] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methanol, ethanol, n-propanol, isopropanol, sec-butanol, tert-butanol, dichloromethane, chloroform or methyl acetate; preferably methanol.

[0026] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form D, and the preparation method of the crystal form D is selected from an anti-solvent addition method or an evaporative crystallization method; preferably, the anti-solvent addition method;

[0027] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from DMSO; and the third solvent is selected from water;

[0028] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from tetrahydrofuran.

[0029] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form E, and the preparation method of the crystal form E is selected from a room temperature suspension method or an anti-solvent addition method, preferably a room temperature suspension method;

[0030] The room temperature suspension method comprises: mixing Ukenafil free base and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from n-hexane, water, or n-heptane;

[0031] The anti-solvent addition method comprises: mixing the free base of Ukenafil and the second solvent, adding the third solvent at 20° C. to 30° C., filtering, and drying to obtain the crystal form of Ukenafil; the second solvent is selected from acetone; and the third solvent is selected from water.

[0032] The third aspect of the present application provides a use of a crystal form of Ukenafil for preparing Ukenafil hydrochloride, wherein the crystal form is selected from any one of crystal form B, crystal form C, crystal form D or crystal form E.

[0033] The present application provides a new crystal form of Ukenafil and a preparation method thereof. After being placed under conditions of high temperature, high humidity and light for a period of time, the crystal forms B, C, D and E all maintain the same crystal form and have good stability, thus overcoming the defect of the instability of the free base of Ukenafil, and facilitating better storage and industrial production of Ukenafil. At the same time, the crystal forms B, C, D and E provided in the present application all have good hygroscopicity and good solubility in various solvents, thus facilitating improving the utilization rate of the reactants and thereby improving the yield of subsequent products.

[0034] Of course, implementing any product or method of the present application does not necessarily require achieving all of the advantages described above at the same time. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other embodiments can also be obtained based on these drawings.

[0036] Figure 1 The XRPD pattern of Ukanafil Form A in Comparative Example 1;

[0037] Figure 2 This is the DVS spectrum of Ukenafil Crystalline Form A in Comparative Example 1;

[0038] Figure 3 The XRPD pattern of Ukenafil Form B in Example 1;

[0039] Figure 4 The DVS spectrum of Ukenafil crystal form B in Example 1;

[0040] Figure 5 The XRPD pattern of Ukanafil Form C in Example 2;

[0041] Figure 6 The DVS spectrum of Ukanafil Crystalline Form C in Example 2;

[0042] Figure 7 The XRPD pattern of Ukanafil Form D in Example 3;

[0043] Figure 8 The DVS spectrum of Ukanafil Crystalline Form D in Example 3;

[0044] Fig. 9 The XRPD pattern of Ukenafil Form E in Example 4;

[0045] Fig.10 The DVS spectrum of Ukenafil Crystalline Form E in Example 4; DETAILED DESCRIPTION

[0046] The following will be combined with the drawings in the embodiments of the present application to clearly and completely describe the technical solutions in the embodiments of the present application. Obviously, the described embodiments are only part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field based on the present application belong to the scope of protection of the present application.

[0047] In a first aspect, the present application provides a crystalline form of Ukenafil represented by formula (I);

[0048]

[0049] Wherein, the crystal form is selected from any one of crystal form B, crystal form C, crystal form D, and crystal form E;

[0050] The X-ray powder diffraction pattern of the crystalline form B includes the following characteristic peaks shown at 2θ angles: 4.953°±0.2°, 9.860°±0.2°, 11.132°±0.2°, 15.708°±0.2°, 17.081°±0.2°, 21.843°±0.2°, 24.120°±0.2°, 24.395°±0.2°, 24.863°±0.2°, 27.306°±0.2°;

[0051] The X-ray powder diffraction pattern of the crystalline form C includes the following characteristic peaks shown at 2θ angles: 9.246°±0.2°, 10.796°±0.2°, 12.167°±0.2°, 13.859°±0.2°, 16.025°±0.2°, 17.455°±0.2°, 17.666°±0.2°, 18.053°±0.2°, 18.710°±0.2°, 20.883°±0.2°;

[0052] The X-ray powder diffraction pattern of the crystalline form D includes the following characteristic peaks shown at 2θ angles: 9.205°±0.2°, 10.638°±0.2°, 11.587°±0.2°, 13.852°±0.2°, 14.874°±0.2°, 15.657°±0.2°, 17.601°±0.2°, 18.558°±0.2°, 19.306°±0.2°, 21.468°±0.2°;

[0053] The X-ray powder diffraction pattern of the crystalline form E includes the following characteristic peaks shown at 2θ angles: 9.383°±0.2°, 9.963°±0.2°, 11.820°±0.2°, 15.848°±0.2°, 16.329°±0.2°, 17.181°±0.2°, 17.803°±0.2°, 20.185°±0.2°, 22.985°±0.2°, and 24.499°±0.2°.

[0054] In some embodiments of the present application, the X-ray powder diffraction pattern of the crystalline form B is substantially as follows Figure 3 shown.

[0055] In some embodiments of the present application, the X-ray powder diffraction pattern of the crystalline form C is substantially as follows Figure 5 shown.

[0056] In some embodiments of the present application, the X-ray powder diffraction pattern of the crystalline form D is substantially as follows: Figure 7 shown.

[0057] In some embodiments of the present application, the X-ray powder diffraction pattern of the crystalline form E is substantially as follows Fig. 9 shown.

[0058] In this application, as stated in “X-ray powder diffraction pattern substantially as Figure 3 In the "shown", the term "substantially" used means that the precise position of the peak in the accompanying drawing should not be interpreted as an absolute value. Because it is known to those skilled in the art that the 2θ value of the X-ray powder diffraction pattern may produce errors due to different measurement conditions (such as the equipment and instruments used) and different samples, the measurement error of the diffraction angle of the X-ray powder diffraction pattern is 5% or less. Generally, a difference of ±0.2° of a given value will be considered appropriate. It should also be understood that the relative intensity of the peak may fluctuate with experimental conditions and sample preparation, such as the preferred orientation of particles in the sample. The use of automatic or fixed divergence slits will also affect the calculation of relative intensities. The intensities shown in the XRPD curves included here are only exemplary and cannot be used as absolute comparisons.

[0059] The second aspect of the present application provides a method for preparing a crystalline form of Ukenafil, wherein the preparation method is selected from any of the following methods: a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method;

[0060] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20° C. to 30° C. for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from at least one of water, methyl tert-butyl ether, C1-C4 alcohol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, DMSO, DMF, n-hexane, or n-heptane;

[0061] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from at least one of acetone, tetrahydrofuran, DMSO, methanol, or DMF; the third solvent is selected from at least one of methyl tert-butyl ether, n-hexane, n-heptane, isopropyl ether, or water;

[0062] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from at least one of methyl tert-butyl ether, C1-C4 alcohol, dichloromethane, chloroform, methyl acetate or tetrahydrofuran.

[0063] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form B, and the preparation method of the crystal form B is selected from a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method; preferably, the anti-solvent addition method;

[0064] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil; the first solvent is selected from at least one of water and methyl tert-butyl ether;

[0065] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20°C to 30°C, filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from acetone, tetrahydrofuran or DMSO; the third solvent is selected from methyl tert-butyl ether, n-hexane or n-heptane; preferably, the second solvent is acetone, and the third solvent is methyl tert-butyl ether; or, preferably, the second solvent is tetrahydrofuran, and the third solvent is methyl tert-butyl ether, n-hexane or n-heptane; or, preferably, the second solvent is DMSO, and the third solvent is n-heptane;

[0066] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methyl tert-butyl ether.

[0067] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form C, and the preparation method of the crystal form C is selected from a room temperature suspension method, an anti-solvent addition method or an evaporative crystallization method; preferably, the room temperature suspension method;

[0068] The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil; the first solvent is selected from methanol, ethanol, n-propanol, n-butanol, isopropanol, sec-butanol, tert-butanol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, DMSO or DMF; preferably tetrahydrofuran;

[0069] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20°C to 30°C, filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from methanol, tetrahydrofuran or DMF; the third solvent is selected from n-hexane or isopropyl ether; preferably, the second solvent is methanol or tetrahydrofuran, and the third solvent is isopropyl ether; or, preferably, the second solvent is DMF, and the third solvent is n-hexane;

[0070] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methanol, ethanol, n-propanol, isopropanol, sec-butanol, tert-butanol, dichloromethane, chloroform or methyl acetate; preferably methanol.

[0071] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form D, and the preparation method of the crystal form D is selected from an anti-solvent addition method or an evaporative crystallization method; preferably, the anti-solvent addition method;

[0072] The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from DMSO; and the third solvent is selected from water;

[0073] The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from tetrahydrofuran.

[0074] The second aspect of the present application provides a method for preparing a crystal form of Ukenafil, wherein the crystal form is crystal form E, and the preparation method of the crystal form E is selected from a room temperature suspension method or an anti-solvent addition method, preferably a room temperature suspension method;

[0075] The room temperature suspension method comprises: mixing Ukenafil free base and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from n-hexane, water, or n-heptane;

[0076] The anti-solvent addition method comprises: mixing the free base of Ukenafil and the second solvent, adding the third solvent at 20° C. to 30° C., filtering, and drying to obtain the crystal form of Ukenafil; the second solvent is selected from acetone; and the third solvent is selected from water.

[0077] The present application has no particular limitation on the drying method, as long as the purpose of the present application can be achieved; preferably, the drying includes vacuum drying at 30°C to 50°C.

[0078] The third aspect of the present application provides a use of a crystal form of Ukenafil for preparing Ukenafil hydrochloride, wherein the crystal form is selected from any one of crystal form B, crystal form C, crystal form D or crystal form E.

[0079] The abbreviations used in this application are explained as follows:

[0080] XRPD: X-ray powder diffraction;

[0081] DVS: dynamic moisture sorption;

[0082] RH: relative humidity.

[0083] In the present application, the term "about" means within ±10% of a value; and the term "room temperature" means 25±5°C.

[0084] The X-ray powder diffraction pattern described in this application was collected on an X-ray powder diffractometer (Bruker D2 Phaser), and the reflection parameters of the X-ray powder diffractometer were set as follows:

[0085] X-ray: Cu, Kα, Kα1 1.54060; Kα2 1.54439, Kα2 / Kα1 intensity ratio: 0.50;

[0086] X-ray tube settings: voltage: 30kV, current: 10mA;

[0087] Divergence slit: 1mm;

[0088] Monochromator: None;

[0089] Scan mode: continuous;

[0090] Approximately 2 mg of sample was collected by lightly compressing it onto an XRPD zero background single bevel cut silica sample holder.

[0091] The dynamic moisture adsorption graph described in the present application was collected on a dynamic moisture adsorption instrument (DVS Intrinsic, SMS company).

[0092] Melting point test: measured by differential scanning calorimeter (DCS 25, TA Company), test temperature range: 25°C ~ 250°C; heating rate: 10°C / min.

[0093] Detection of related substances: Agilent 1260 liquid chromatograph was used to determine according to the high performance liquid chromatography method, with octadecylsilane bonded silica gel as the filler, 0.02 mol / L ammonium acetate aqueous solution (adjusted to pH 5.8 with glacial acetic acid)-acetonitrile (volume ratio of 90:10) as mobile phase A, 0.02 mol / L ammonium acetate aqueous solution (adjusted to pH 5.8 with glacial acetic acid)-acetonitrile (volume ratio of 10:90) as mobile phase B, and gradient elution was performed; the flow rate was 1 mL per minute; the detection wavelength was 240 nm; the column temperature was 40°C; the injection volume was 20 μL; the injection plate temperature was 10°C.

[0094] In the HPLC test, the relevant test parameters are as follows:

[0095]

[0096]

[0097] Diluent: acetonitrile-water (volume ratio 50:50).

[0098] Test solution: Take an appropriate amount of crystalline form of Ukenafil, add diluent, shake to dissolve, and dilute to make a solution containing approximately 1 mg of Ukenafil per 1 mL.

[0099] Control solution: Accurately measure an appropriate amount of the Ukenafil reference substance and dilute it with a diluent to make a solution containing approximately 10 μg of Ukenafil per 1 mL.

[0100] Determination method: Accurately measure the control solution and the test solution, inject them into the liquid chromatograph respectively, record the chromatogram, and calculate the content of related substances according to the main component self-reference method.

[0101] Preparation Example 1: Preparation of Ukenafil Free Base

[0102] Step 1:

[0103] 2-Ethoxybenzoic acid (320.00 g, 1.92 mol) was mixed with thionyl chloride (0.60 L) for reaction, stirred and refluxed for 1 h, and then concentrated by distillation under reduced pressure. The concentrate was further dissolved in dichloromethane (2.0 L), and further stirred and added dropwise to a mixed solution of 2-amino-3-cyano-4-methylpyrrole (224.0 g, 1.82 mol), tetrahydrofuran (2.60 L) and triethylamine (0.28 L, 1.96 mol) at 0 ° C. After the addition was completed, stirring was continued for 1 h. After the reaction was completed, the mixture was washed with water, filtered and dried, and purified by column chromatography (dichloromethane: n-hexane volume ratio of 1:2) to obtain 240 g of solid product N-(3-cyano-4-methyl-1H-pyrrol-2-yl)-2-ethoxybenzamide (intermediate 1).

[0104] Step 2:

[0105] The intermediate 1 (64 g) obtained in step 1 was mixed with phosphoric acid solution (0.48 L), stirred at 120-130° C. for 30 min, and cooled to obtain 54.4 g of solid 2-(2-ethoxybenzamide)-4-methyl-1H-pyrrole-3-carboxamide (intermediate 2) after filtration and drying.

[0106] Step 3:

[0107] The intermediate 2 obtained in step 2 was reacted with dimethylcyclohexylamine (0.30 L), and the reaction was stirred and refluxed in N,N-dimethylformamide (DMF, 0.8 L) solvent for 10 h. After reduced pressure concentration, the mixture was washed with water and dried, and then filtered and purified to obtain 46.2 g of the product 2-(2-ethoxyphenyl)-5-methyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (intermediate 3).

[0108] Step 4:

[0109] The intermediate 3 obtained in step 3 was mixed with n-propane bromide (64.0 g, 0.52 mol) and potassium carbonate (160 g, 1.16 mol) in acetone (0.45 L) and heated with stirring under reflux for 15 hours. After filtering off the solid, the mixture was evaporated to dryness under reduced pressure and purified by column chromatography (developing solvent: dichloromethane) to obtain 19.20 g of the product 2-(2-ethoxyphenyl)-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one (intermediate 4).

[0110] Step 5:

[0111] The intermediate 4 obtained in step 4 was added to a mixed solution of chlorosulfonic acid (128 mL) and ethyl acetate (0.64 L) at 0°C. The reaction was maintained at 0°C for 30 min, and then stirred at room temperature for 3 h. Finally, the reaction solution was poured into a mixture of ice water (0.6 L) and ethyl acetate (0.6 L) for separation. The organic layer was washed with cold water, dried and evaporated to obtain 20.4 g of the product 4-ethoxy-3-(5-methyl-4-oxo-7-n-propyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-2-yl)-benzenesulfonyl chloride (intermediate 5).

[0112] Step 6:

[0113] The intermediate 5 obtained in step 5 was dissolved in dichloromethane (0.64 L). 1-Ethylpiperazine (24.96 mL, 195.20 mmol) was slowly added. The reaction solution was stirred at 0°C for 5 minutes, and then stirred at room temperature for 5 hours. Washed with water, dried over anhydrous sodium sulfate and evaporated to dryness to obtain 24.8 g of yellow foamy product. Column chromatography (ethyl acetate: methanol volume ratio of 20: 1) obtained 18.2 g of solid, i.e., free base of Ukenafil.

[0114] Comparative Example 1: Preparation of Ukanafil Crystalline Form A (Room Temperature Suspension Method)

[0115] 2 g of the free base of Ukenafil prepared in Preparation Example 1 and 10 mL of acetonitrile were added to a 150 mL jacketed bottle, stirred at 25 ° C for 4 h, filtered and dried at 50 ° C in vacuum to obtain 1.78 g of a white solid with a melting point of 177.40 ° C. XRPD detection showed that it was Form A. The X-ray powder diffraction pattern was as follows: Figure 1 Its X-ray powder diffraction data are shown in Table 1:

[0116] Table 1

[0117] Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity 7.100 280 15.613 25.5 24.456 59.6 9.413 193 17.403 952 25.626 41.9 9.947 577 18.042 49.9 25.626 41.9 10.913 504 18.756 62.7 27.108 74.3 11.739 59.8 19.046 427 28.066 18.6 12.056 351 19.666 188 28.107 12.3 12.666 95.1 20.299 180 29.647 16.8 13.303 507 20.728 49.8 30.516 22.3 13.819 37.3 21.076 76.8 31.029 32.4 14.374 138 21.702 362 31.755 12.7 14.628 510 23.858 106 32.435 22.2 15.169 227 24.188 78.8 37.000 36.4

[0118] Example 1: Preparation of Ukenafil Form B (Anti-solvent Addition Method)

[0119] Take 2g of the free base of Ukenafil prepared in Preparation Example 1 and 10mL of tetrahydrofuran, add them into a 150mL jacketed bottle, stir and dissolve at 25°C, add 100mL of methyl tert-butyl ether, crystallize at 25°C for 5h, filter, and dry in vacuo at 40°C to obtain 1.45g of a white solid with a melting point of 177.07°C. XRPD detection shows that it is Form B. The X-ray powder diffraction pattern is as follows: Figure 3 Its X-ray powder diffraction data are shown in Table 2:

[0120] Table 2

[0121] Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity 4.953 1454 20.096 354 26.981 76.4 9.860 7657 20.651 59.3 27.306 244 11.132 685 21.166 29.0 27.925 65.9 12.249 142 21.843 213 28.705 19.9 14.278 107 22.893 22.1 29.949 190 14.812 182 23.225 142 30.349 75.6 15.171 63.3 23.581 35.9 30.965 18.6 15.708 192 24.120 200 32.366 48.4 16.232 124 24.395 395 35.088 70.8 17.081 192 24.863 203 36.663 18.3 17.979 111 25.373 49.6 38.952 29.6 18.343 24.3 25.753 35.3 / / 19.896 131 26.492 19.5 / /

[0122] Note: “ / ” in Table 2 means not present.

[0123] Example 2: Preparation of Ukanafil Crystalline Form C (Evaporation Crystallization Method)

[0124] 2 g of the free base of Ukenafil prepared in Preparation Example 1 and 20 mL of methanol were added to a 150 mL jacketed bottle, stirred at 25°C and filtered, the filtrate was slowly evaporated, the solid obtained was filtered, and vacuum dried at 40°C to obtain 0.95 g of a white solid with a melting point of 167.56°C. XRPD detection showed that it was Form C, and the X-ray powder diffraction pattern was as follows: Figure 5 Its X-ray powder diffraction data are shown in Table 3:

[0125] Table 3

[0126]

[0127]

[0128] Note: “ / ” in Table 3 means not present.

[0129] Example 3: Preparation of Ukenafil Form D (Anti-solvent Addition Method)

[0130] Take 2g of the free base of Ukenafil prepared in Preparation Example 1 and 20mL of DMSO, add them to a 150mL jacketed bottle, beat at 25°C for 5h, filter to obtain the filtrate, slowly add 100mL of water, stir well at 25°C, filter, and vacuum dry at 40°C to obtain 0.95g of a white solid with a melting point of 177.06°C. It was detected by XRPD to be Form D, and the X-ray powder diffraction pattern is as follows: Figure 7 Its X-ray powder diffraction data are shown in Table 4:

[0131] Table 4

[0132] Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity Diffraction angle 2θ Peak intensity 7.043 77.6 17.601 633 24.259 80.5 9.205 434 18.089 54.2 24.786 39.1 10.638 270 18.558 158 25.229 61.2 11.587 174 19.306 233 25.776 77.3 12.221 41.2 19.817 40.5 26.876 31.2 12.492 58.8 20.837 65.8 28.091 24.9 13.852 318 21.468 186 28.565 41.0 14.874 232 22.082 87.4 30.607 29.4 15.657 360 22.788 109 34.604 12.0 16.069 108 23.523 56.3 35.711 28.3 16.962 27.5 23.949 165 / /

[0133] Note: “ / ” in Table 4 means not present.

[0134] Example 4: Preparation of Ukanafil Crystalline Form E (Room Temperature Suspension Method)

[0135] Take 2g of the free base of Ukenafil prepared in Preparation Example 1 and 10mL of n-hexane, add them to a 150mL jacketed bottle, beat at 25°C for 5h, filter, and vacuum dry at 40°C to obtain 1.98g of a white solid with a melting point of 176.18°C. XRPD detection showed that it was Form E. The X-ray powder diffraction pattern was as follows: Fig. 9 Its X-ray powder diffraction data are shown in Table 5:

[0136] Table 5

[0137]

[0138]

[0139] Note: “ / ” in Table 5 means not present.

[0140] Example 5-23: Preparation of Uknafil Crystalline Form by Room Temperature Suspension Method

[0141] Except for adjusting the relevant parameters according to Example 4, the rest is the same as Example 4. The relevant parameter changes of Examples 5-23 and the quality of the obtained products are shown in Table 6:

[0142] Table 6

[0143] / First solvent temperature Mixing time The obtained crystal form The quality of the obtained crystal Example 5 water Room temperature 4h Crystal Form E 1.70g Example 6 Methyl tert-butyl ether Room temperature 4h Crystalline Form B 1.60g Example 7 Methanol Room temperature 4h Form C 1.80g Example 8 Ethanol Room temperature 4h Form C 1.40g Example 9 n-Propanol Room temperature 4h Form C 1.40g Example 10 n-Butanol Room temperature 4h Form C 1.40g Embodiment 11 Isopropyl alcohol Room temperature 4h Form C 1.40g Example 12 Sec-Butanol Room temperature 4h Form C 1.40g Example 13 Tert-Butanol Room temperature 4h Form C 1.20g Embodiment 14 Methyl isobutyl ketone Room temperature 4h Form C 1.30g Embodiment 15 Ethyl formate Room temperature 4h Form C 1.30g Example 16 Methyl acetate Room temperature 4h Form C 1.20g Embodiment 17 Isopropyl acetate Room temperature 4h Crystalline Form C 1.30g Embodiment 18 Butyl acetate Room temperature 4h Form C 1.30g Embodiment 19 Tetrahydrofuran Room temperature 4h Form C 1.40g Embodiment 20 Isopropyl ether Room temperature 4h Crystalline Form C 1.20g Embodiment 21 DMSO Room temperature 4h Form C 1.20g Embodiment 22 DMF Room temperature 4h Form C 1.30g Embodiment 23 n-Heptane Room temperature 4h Crystal Form E 1.30g

[0144] Example 24-31: Preparation of Ukenafil Crystalline Forms by Anti-Solvent Addition Method

[0145] Except for adjusting relevant parameters according to Example 1, the rest is the same as Example 1.

[0146] The relevant parameter changes of Examples 24-31 and the quality of the obtained products are shown in Table 7:

[0147] Table 7

[0148] / Secondary solvent The third solvent Stirring temperature The obtained crystal form The quality of the obtained crystal Embodiment 24 acetone Methyl tert-butyl ether Room temperature Crystalline Form B 0.80g Embodiment 25 Tetrahydrofuran n-Hexane Room temperature Crystalline Form B 0.95g Embodiment 26 Tetrahydrofuran n-Heptane Room temperature Crystalline Form B 1.05g Embodiment 27 DMSO n-Heptane Room temperature Crystalline Form B 0.70g Embodiment 28 Methanol Isopropyl ether Room temperature Form C 1.10g Embodiment 29 Tetrahydrofuran Isopropyl ether Room temperature Form C 0.90g Embodiment 30 DMF n-Hexane Room temperature Form C 1.10g Embodiment 31 acetone water Room temperature Crystal Form E 1.00g

[0149] Examples 32-41: Preparation of Uknafil Crystalline Forms by Evaporative Crystallization

[0150] Except for adjusting relevant parameters according to Example 2, the rest is the same as Example 2.

[0151] The relevant parameter changes of Examples 32-41 and the quality of the obtained products are shown in Table 8:

[0152] Table 8

[0153] / The fourth solvent Stirring temperature The obtained crystal form The quality of the obtained crystal Embodiment 32 Methyl tert-butyl ether Room temperature Crystalline Form B 0.90g Embodiment 33 Ethanol Room temperature Form C 0.95g Embodiment 34 n-Propanol Room temperature Form C 1.00g Embodiment 35 Isopropyl alcohol Room temperature Form C 0.70g Embodiment 36 Sec-Butanol Room temperature Form C 0.70g Embodiment 37 Tert-Butanol Room temperature Crystalline Form C 0.70g Embodiment 38 Dichloromethane Room temperature Form C 0.80g Embodiment 39 Chloroform Room temperature Crystalline Form C 0.90g Embodiment 40 Methyl acetate Room temperature Crystalline Form C 0.90g Embodiment 41 Tetrahydrofuran Room temperature Crystal form D 0.95g

[0154] Example 42: Stability of Ukenafil Crystalline Form

[0155] The stability of the Ukalafil crystal form A, crystal form B, crystal form D, crystal form C, and crystal form D provided in the present application was investigated. Specifically, the changes in the crystal form were investigated by placing each crystal form under different storage conditions to measure the stability of the crystal form to high temperature, high humidity, light and other conditions. The storage conditions and results are shown in Table 9:

[0156] Table 9

[0157]

[0158] It can be seen from Table 9 that after being placed for 30 days, Form B, Form C, Form D, and Form E can maintain their crystal forms unchanged under high temperature, high humidity, and light conditions, while Form A will undergo crystal transformation under high temperature and high humidity conditions, indicating that Form B, Form C, Form D, and Form E provided in the present application have better stability than Form A.

[0159] In order to further verify the relative stability of Form B, Form C, Form D and Form E, the changes of related substances under different storage conditions were evaluated. The storage conditions and impurity contents are shown in Table 10:

[0160] Table 10

[0161]

[0162] It can be seen from Table 10 that under high temperature conditions, Form C and Form D are more stable than Form A, among which Form C is the more stable form and Form D is the less stable form; under light conditions, the stability of Form C, Form D and Form E are significantly better than Form A, among which Form D is the more stable form and Form C is the less stable form.

[0163] In summary, Form B, Form C, Form D, and Form E all have good stability, among which Form C and Form D have better stability.

[0164] Example 43: Hygroscopicity of Ukanafil Crystalline Form

[0165] About 20 mg of Ukanafil crystal form A, crystal form B, crystal form C, crystal form D, and crystal form E were weighed separately and placed in a dynamic moisture sorption instrument (SMS), and then dried by keeping each crystal form sample at 0% RH until no further weight change was recorded. Subsequently, the sample was slowly distributed from 0 to 95% RH with a weight increase of 10% RH, and the sample was kept at each step until equilibrium was reached. When equilibrium was reached, the humidity in the instrument was slowly changed to the next step, and the equilibrium process was repeated. After the adsorption cycle was completed, the sample was dried using the same distribution procedure from 95% RH to 0% RH with a 10% RH increment. Finally, the sample was dried by keeping it in a 0% RH environment until no further weight change was recorded. The weight change during the adsorption / desorption cycle was then detected for the determination of the hygroscopic properties of the sample, and the DVS spectra of each crystal form sample were obtained as shown below. Figure 2 , Figure 4 , Figure 6 , Figure 8 , Fig.10 The weight change results during the adsorption / desorption cycle are shown in Table 11:

[0166] Table 11

[0167] humidity Crystalline Form A Crystalline Form B Form C Crystal form D Crystalline Form E 60%RH 0.08% 0.02% 0.23% 0.25% 0.24% 80%RH 0.33% 0.25% 0.38% 0.56% 0.42% 95%RH 0.88% 1.07% 0.64% 1.15% 0.69%

[0168] It can be seen from Table 11 that the moisture gain of each crystal form of Ukenafil under various humidity conditions is less than 2%. It can be seen that the Ukenafil crystal form B, crystal form C, crystal form D, and crystal form E provided in the present application all have good hygroscopicity, and there is no significant difference compared with crystal form A.

[0169] Example 44: Solubility of Ukanafil Crystalline Form

[0170] Take appropriate amounts of Ukenafil Form A, Form B, Form C, Form D, and Form E (about 10-20 mg) respectively, place in a constant temperature mixer at 25°C, slowly add to the test solvents shown in Table 12 and shake, record the amount of solvent before and after dissolution, calculate the solubility, and the results are shown in Table 12, in mg / mL.

[0171] Table 12

[0172]

[0173] It can be seen from Table 12 that the ukenafil crystal form B, crystal form C, crystal form D, and crystal form E provided in the present application have similar solubility in various solutions; in the ethyl acetate / dichloromethane mixed solvent, the crystal form E exhibits better solubility, and the ethyl acetate / dichloromethane mixed solvent can be further used to prepare ukenafil into ukenafil hydrochloride.

[0174] In summary, the crystalline form B, crystalline form C, crystalline form D, and crystalline form E provided in the present application all have the effects of high stability, good hygroscopicity, and good solubility, which are beneficial to improving the utilization rate of the reactants and thus improving the yield of subsequent products.

[0175] The above description is only a preferred embodiment of the present application and is not intended to limit the present application. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present application shall be included in the scope of protection of the present application.

Claims

1. A crystalline form of Ukenafil represented by formula (I); in, The crystal form is selected from any one of crystal form B, crystal form C, crystal form D, and crystal form E; The X-ray powder diffraction pattern of the crystalline form B includes the following characteristic peaks shown at 2θ angles: 4.953°±0.2°, 9.860°±0.2°, 11.132°±0.2°, 15.708°±0.2°, 17.081°±0.2°, 21.843°±0.2°, 24.120°±0.2°, 24.395°±0.2°, 24.863°±0.2°, 27.306°±0.2°; The X-ray powder diffraction pattern of the crystalline form C includes the following characteristic peaks shown at 2θ angles: 9.246°±0.2°, 10.796°±0.2°, 12.167°±0.2°, 13.859°±0.2°, 16.025°±0.2°, 17.455°±0.2°, 17.666°±0.2°, 18.053°±0.2°, 18.710°±0.2°, 20.883°±0.2°; The X-ray powder diffraction pattern of the crystalline form D includes the following characteristic peaks shown at 2θ angles: 9.205°±0.2°, 10.638°±0.2°, 11.587°±0.2°, 13.852°±0.2°, 14.874°±0.2°, 15.657°±0.2°, 17.601°±0.2°, 18.558°±0.2°, 19.306°±0.2°, 21.468°±0.2°; The X-ray powder diffraction pattern of the crystalline form E includes the following characteristic peaks shown at 2θ angles: 9.383°±0.2°, 9.963°±0.2°, 11.820°±0.2°, 15.848°±0.2°, 16.329°±0.2°, 17.181°±0.2°, 17.803°±0.2°, 20.185°±0.2°, 22.985°±0.2°, and 24.499°±0.2°.

2. The crystalline form of Ukenafil according to claim 1, in, The crystal form is crystal form B, and the X-ray powder diffraction pattern of the crystal form B is basically as shown in Figure 3.

3. The crystal form of Ukenafil according to claim 1, in, The crystal form is crystal form C, and the X-ray powder diffraction pattern of the crystal form C is substantially as shown in FIG5 .

4. The crystalline form of Ukenafil according to claim 1, in, The crystal form is crystal form D, and the X-ray powder diffraction pattern of the crystal form D is substantially as shown in FIG. 7 .

5. The crystal form of Ukenafil according to claim 1, in, The crystal form is crystal form E, and the X-ray powder diffraction pattern of the crystal form E is basically as shown in Figure 9.

6. A method for preparing the crystal form of Ukenafil according to claim 1, in, The preparation method is selected from any of the following methods: room temperature suspension method, anti-solvent addition method or evaporation crystallization method; The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20° C. to 30° C. for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from water, methyl tert-butyl ether, C 1 -C 4 At least one of alcohol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, DMSO, DMF, n-hexane or n-heptane; The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from at least one of acetone, tetrahydrofuran, DMSO, methanol, or DMF; the third solvent is selected from at least one of methyl tert-butyl ether, n-hexane, n-heptane, isopropyl ether, or water; The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methyl tert-butyl ether, C 1 -C 4 At least one of alcohol, dichloromethane, chloroform, methyl acetate or tetrahydrofuran.

7. The preparation method according to claim 6, in, The crystal form is crystal form B, and the preparation method of the crystal form B is selected from room temperature suspension method, anti-solvent addition method or evaporation crystallization method; preferably, the anti-solvent addition method; Wherein, the room temperature suspension method comprises: mixing the free base of Ukenafil and the first solvent, stirring for 2 to 6 hours at 20°C to 30°C, filtering, and drying to obtain the crystal form of Ukenafil, wherein the first solvent is selected from methyl tert-butyl ether; the anti-solvent addition method comprises: mixing the free base of Ukenafil and the second solvent, adding the third solvent at 20°C to 30°C, filtering, and drying to obtain the crystal form of Ukenafil; the second solvent is selected from acetone, tetrahydrofuran or DMSO; the third solvent is selected from methyl tert-butyl ether, n-hexane or n-heptane; preferably, the second solvent is acetone, and the third solvent is methyl tert-butyl ether; or, preferably, the second solvent is tetrahydrofuran, and the third solvent is methyl tert-butyl ether, n-hexane or n-heptane; or, preferably, the second solvent is DMSO, and the third solvent is n-heptane; The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methyl tert-butyl ether.

8. A preparation method according to claim 6, in, The crystal form is crystal form C, and the preparation method of the crystal form C is selected from room temperature suspension method, anti-solvent addition method or evaporation crystallization method; preferably room temperature suspension method; The room temperature suspension method comprises: mixing the free base of Ukenafil and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil; the first solvent is selected from methanol, ethanol, n-propanol, n-butanol, isopropanol, sec-butanol, tert-butanol, methyl isobutyl ketone, ethyl formate, methyl acetate, isopropyl acetate, butyl acetate, tetrahydrofuran, isopropyl ether, DMSO or DMF; preferably tetrahydrofuran; The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20°C to 30°C, filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from methanol, tetrahydrofuran or DMF; the third solvent is selected from n-hexane or isopropyl ether; preferably, the second solvent is methanol or tetrahydrofuran, and the third solvent is isopropyl ether; or, preferably, the second solvent is DMF, and the third solvent is n-hexane; The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from methanol, ethanol, n-propanol, isopropanol, sec-butanol, tert-butanol, dichloromethane, chloroform or methyl acetate; preferably methanol.

9. A preparation method according to claim 6, in, The crystal form is crystal form D, and the preparation method of the crystal form D is selected from the anti-solvent addition method or the evaporative crystallization method; preferably the anti-solvent addition method; The anti-solvent addition method comprises: mixing the free base of Ukenafil with a second solvent, adding a third solvent at 20° C. to 30° C., filtering, and drying to obtain a crystalline form of Ukenafil; the second solvent is selected from DMSO; and the third solvent is selected from water; The evaporative crystallization method comprises: mixing the free base of Ukenafil and a fourth solvent, filtering, slowly evaporating the filtrate and filtering to obtain a solid, and drying to obtain a crystalline form of Ukenafil; the fourth solvent is selected from tetrahydrofuran.

10. A preparation method according to claim 6, in, The crystal form is crystal form E, and the preparation method of the crystal form E is selected from a room temperature suspension method or an anti-solvent addition method, preferably a room temperature suspension method; The room temperature suspension method comprises: mixing Ukenafil free base and a first solvent, stirring at 20°C to 30°C for 2 to 6 hours, filtering, and drying to obtain a crystalline form of Ukenafil, wherein the first solvent is selected from n-hexane, water, or n-heptane; The anti-solvent addition method comprises: mixing the free base of Ukenafil and the second solvent, adding the third solvent at 20° C. to 30° C., filtering, and drying to obtain the crystal form of Ukenafil; the second solvent is selected from acetone; and the third solvent is selected from water.

11. Use of the crystal form of Uknafil according to claim 1 for preparing Uknafil hydrochloride, in, The crystal form is selected from any one of crystal form B, crystal form C, crystal form D or crystal form E.